DMAC · DiaMedica Therapeutics Inc
United States · RS rating 84 · As of 2026-10-14
| Price | 7.66 USD |
|---|---|
| 1-day change | -2.0% |
| RS rating (overall / 1M / 3M / 12M) | 84 / 96 / 83 / 58 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 35 / 43 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +18.4% |
| Market cap (USD) | $335.1M |